Clinical Trial Update: A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating PLB1001 in patients with non-small cell lung cancer that have c-Met dysregulation; the study status is ACTIVE_NOT_RECRUITING…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PLB1001

Snippet

Sponsor: Beijing Pearl Biotechnology Limited Liability Company | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING